Insulin Manufacturing Expansion

Eli Lilly and Company (NYSE: LLY) today (Nov 14) announced it will invest more than $700 million to enhance its global insulin manufacturing capacity in Puerto Rico, France and China, as well as in Indianapolis, home to Lilly’s global headquarters. Today’s news raises Lilly’s manufacturing commitment in the past year to more than $1 billion in planned investments in response to the growing diabetes epidemic and increasing demand for insulin around the world.
Read more about the new manufacturing investments here.